Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Files BLA For VEGF Trap-Eye In Wet AMD; Second Filing Anticipated This Year

This article was originally published in The Pink Sheet Daily

Executive Summary

If the ophthalmic product wins priority review, Roche could see competition for Lucentis in wet AMD by the fall.

You may also be interested in...



Regeneron/Bayer's Wet AMD Drug Goes Before FDA Panel In June

Regneron and Bayer likely to tout aflibercept's better dosing schedule over Lucentis and may seek further differentiation in wake of Lucentis v. Avastin study.

Regeneron/Bayer's Wet AMD Drug Goes Before FDA Panel In June

Regneron and Bayer likely to tout aflibercept's better dosing schedule over Lucentis and may seek further differentiation in wake of Lucentis v. Avastin study.

Survival Benefit May Position Zaltrap To Compete With Avastin In Second-Line CRC

Full results of the trial will show how Sanofi-Aventis/Regeneron's VEGF Trap performs in patients who have been on Avastin, as well as how the survival advantage stacks up against Avastin.

Related Content

Topics

UsernamePublicRestriction

Register

PS071868

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel